Three health systems filed a federal lawsuit this month alleging CVS Health improperly diverted approximately $250 million [1] in drug pricing savings.
The legal action targets the core of the 340B Drug Pricing Program, which is designed to help safety-net providers stretch limited federal resources to reach more patients. If the allegations are proven, it suggests a systemic failure in how contracted pharmacies handle discounts intended for hospitals rather than corporate entities.
The plaintiffs include the Mount Sinai Health System, which encompasses St. Luke's-Roosevelt Hospital and Mount Sinai Beth Israel, the University of Kansas Hospital Authority, and the University of Michigan Health System [2]. The lawsuit was filed in May 2026 [4] in a U.S. federal court.
According to the filing, CVS Health and its pharmacy subsidiaries used "spread pricing" to artificially deflate the reimbursements for 340B drugs [5]. The health systems allege that CVS pocketed these savings instead of passing them through to the providers [5]. This activity allegedly occurred over a five-year period between 2020 and 2025 [1].
The 340B program allows eligible hospitals to purchase outpatient drugs at significantly reduced prices. The plaintiffs said the actions of CVS Health violated the fundamental purpose of the program by redirecting funds that should have supported patient care [5].
CVS Health has not yet issued a formal response to the specific allegations in the federal filing. The case now moves toward the discovery phase to determine the exact scale of the diverted funds and whether the company's reimbursement practices breached its contractual or legal obligations to the participating health systems [3].
“Three health systems filed a federal lawsuit this month alleging CVS Health improperly diverted approximately $250 million in drug pricing savings.”
This lawsuit highlights a growing tension between the federal government's goal of expanding healthcare access through the 340B program and the profit motives of large pharmacy benefit managers. If the court finds that spread pricing was used to siphon 340B funds, it could trigger broader regulatory scrutiny of how pharmacy subsidiaries manage drug discounts and may lead to a restructuring of contractor agreements nationwide.
